{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:46:12Z","timestamp":1793724372688,"version":"4.6.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/yco.0b013e32835f414b","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T22:32:53Z","timestamp":1363991573000},"page":"252-259","source":"Crossref","is-referenced-by-count":116,"title":["Agitation and aggression in people with Alzheimer's disease"],"prefix":"10.1097","volume":"26","author":[{"given":"Clive","family":"Ballard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-5-20210206","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","article-title":"Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging.","volume":"157","author":"Lyketsos","year":"2000","journal-title":"Am J Psych"},{"key":"R3-5-20210206","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/1099-1166(200101)16:1<39::AID-GPS269>3.0.CO;2-F","article-title":"Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments.","volume":"16","author":"Margallo-Lana","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"R4-5-20210206","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1017\/S104161020700484X","article-title":"Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments.","volume":"19","author":"Lyketsos","year":"2007","journal-title":"Int Psychogeriatr"},{"key":"R5-5-20210206","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/jnp.3.4.371","article-title":"Hallucinations and associated factors in Alzheimers disease.","volume":"3","author":"Gilley","year":"1991","journal-title":"J Neuropsych Clin Neurosci"},{"key":"R6-5-20210206","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jama.1982.03330030039022","article-title":"The impact of dementia on the family.","volume":"248","author":"Rabins","year":"1982","journal-title":"JAMA"},{"key":"R7-5-20210206","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/bmj.312.7036.947","article-title":"A follow up study of depression in the carers of dementia sufferers.","volume":"312","author":"Ballard","year":"1996","journal-title":"BMJ"},{"key":"R8-5-20210206","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/jnnp.2005.072983","article-title":"Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia.","volume":"77","author":"Banerjee","year":"2006","journal-title":"J Neurol Neurosurg Psych"},{"key":"R9-5-20210206","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1176\/ajp.147.8.1049","article-title":"Psychiatric symptoms and nursing home placement of patients with Alzheimers disease.","volume":"147","author":"Steele","year":"1990","journal-title":"Am J Psych"},{"key":"R10-5-20210206","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pain.2007.03.023","article-title":"The utility of pain assessment for analgesic use in persons with dementia.","volume":"134","author":"Cohen-Mansfield","year":"2008","journal-title":"Pain"},{"key":"R11-5-20210206","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.JGP.0000221334.65330.55","article-title":"Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia due to Alzheimer disease.","volume":"14","author":"Lyketsos","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"R12-5-20210206","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/gerona\/62.8.908","article-title":"Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention.","volume":"62","author":"Cohen-Mansfield","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R13-5-20210206","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/gerona\/52A.6.M369","article-title":"Management of verbally disruptive behaviors in nursing home residents.","volume":"52","author":"Cohen-Mansfield","year":"1997","journal-title":"J Gerontol Series A-Biol Sci Med Sci"},{"key":"R14-5-20210206","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.JGP.0000300629.35408.94","article-title":"Tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden: a randomized pilot study.","volume":"16","author":"Gitlin","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"R15-5-20210206","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JGP.0b013e3181b0f8c0","article-title":"Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (The CALM-AD Trial).","volume":"17","author":"Ballard","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"R17-5-20210206","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/bmj.38782.575868.7C","article-title":"Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomized trial.","volume":"332","author":"Fossey","year":"2006","journal-title":"BMJ"},{"key":"R18-5-20210206","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/gps.543","article-title":"Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities.","volume":"17","author":"Ballard","year":"2002","journal-title":"Int J Geriatric Psychiatry"},{"key":"R19-5-20210206","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(09)70045-6","article-title":"Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial.","volume":"8","author":"Chenoweth","year":"2009","journal-title":"Lancet Neurol"},{"key":"R20-5-20210206","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1532-5415.1990.tb02407.x","article-title":"A metaanalysis of controlled trials of neuroleptic treatment in dementia.","volume":"38","author":"Schneider","year":"1990","journal-title":"J Am Geriatr Soc"},{"key":"R22-5-20210206","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0193-953X(18)30312-5","article-title":"Neuroleptic drugs in the management of behavioral symptoms of Alzheimers disease.","volume":"14","author":"Tune","year":"1991","journal-title":"Psychiatr Clin North Am"},{"key":"R23-5-20210206","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet"},{"key":"R24-5-20210206","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrn1926","article-title":"Neuroleptic drugs in dementia: benefits and harm.","volume":"7","author":"Ballard","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"R25-5-20210206","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.","volume":"14","author":"Schneider","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"R26-5-20210206","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimers disease.","volume":"355","author":"Schneider","year":"2006","journal-title":"N Engl J Med"},{"key":"R28-5-20210206","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"R29-5-20210206","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet Neurol"},{"key":"R30-5-20210206","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications.","volume":"353","author":"Wang","year":"2005","journal-title":"N Engl J Med"},{"key":"R31-5-20210206","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1517\/14740338.2010.506711","article-title":"Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality.","volume":"10","author":"Ballard","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"R32-5-20210206","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3233\/JAD-2009-1031","article-title":"Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102TC) in Alzheimers disease: a 3-year follow-up longitudinal study.","volume":"17","author":"Angelucci","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"R33-5-20210206","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/YIC.0b013e328333ee10","article-title":"Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.","volume":"25","author":"Dombrovski","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"R34-5-20210206","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1136\/bmj.d4065","article-title":"Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial.","volume":"343","author":"Husebo","year":"2011","journal-title":"BMJ"},{"key":"R35-5-20210206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.289.2.210","article-title":"Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.","volume":"289","author":"Trinh","year":"2003","journal-title":"JAMA"},{"key":"R36-5-20210206","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"key":"R37-5-20210206","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimers disease: randomised double blind placebo controlled trial.","volume":"330","author":"Ballard","year":"2005","journal-title":"BMJ"},{"key":"R38-5-20210206","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimers disease.","volume":"357","author":"Howard","year":"2007","journal-title":"N Engl J Med"},{"key":"R39-5-20210206","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"R40-5-20210206","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1017\/S104161020200858X","article-title":"Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimers disease.","volume":"14","author":"Gauthier","year":"2002","journal-title":"Int Psychogeriatr"},{"key":"R41-5-20210206","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/gps.1341","article-title":"Effects of memantine on behavioural symptoms in Alzheimers disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.","volume":"20","author":"Gauthier","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"key":"R43-5-20210206","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/gps.1949","article-title":"Improvement in behavioural symptoms in patients with moderate to severe Alzheimers disease by memantine: a pooled data analysis.","volume":"23","author":"Gauthier","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"key":"R44-5-20210206","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","article-title":"Memantine for agitationaggression and psychosis in moderately severe to severe Alzheimers disease: a pooled analysis of 3 studies.","volume":"69","author":"Wilcock","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R45-5-20210206","doi-asserted-by":"crossref","first-page":"e35185","DOI":"10.1371\/journal.pone.0035185","article-title":"Efficacy of memantine for agitation in Alzheimers dementia: a randomised double-blind placebo controlled trial.","volume":"7","author":"Fox","year":"2012","journal-title":"PLoS One"},{"key":"R46-5-20210206","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimers disease.","volume":"366","author":"Howard","year":"2012","journal-title":"N Engl J Med"},{"key":"R47-5-20210206","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.","volume":"159","author":"Pollock","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R48-5-20210206","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A doubleblind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.","volume":"15","author":"Pollock","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"R49-5-20210206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/gps.998","article-title":"A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimers disease in outpatients treated with donepezil.","volume":"19","author":"Finkel","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"R50-5-20210206","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","article-title":"Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.","volume":"55","author":"Teri","year":"2000","journal-title":"Neurology"},{"key":"R51-5-20210206","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/ajp.155.1.54","article-title":"Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.","volume":"155","author":"Tariot","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R52-5-20210206","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00019442-200111000-00008","article-title":"A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease.","volume":"9","author":"Olin","year":"2001","journal-title":"Am J Geriatr Psychiatry"},{"key":"R53-5-20210206","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S1041610207006540","article-title":"Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review.","volume":"20","author":"Konovalov","year":"2008","journal-title":"Int Psychogeriatr"},{"key":"R54-5-20210206","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.JGP.0000237065.78966.1b","article-title":"Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease.","volume":"15","author":"Sharp","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"R55-5-20210206","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","article-title":"Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.","volume":"17","author":"Wang","year":"2009","journal-title":"Am J Geriatr Psychiatry"}],"container-title":["Current Opinion in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/YCO.0b013e32835f414b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:47:34Z","timestamp":1620978454000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001504-201305000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/yco.0b013e32835f414b","relation":{},"ISSN":["0951-7367"],"issn-type":[{"value":"0951-7367","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}